10-QPeriod: Q3 FY2011

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2011

Filed November 3, 2011For Securities:ALNY

Summary

This 10-Q filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY) as of November 3, 2011, covers the unaudited financial results for the nine months ended September 30, 2011. Investors should note the company is in the development stage, as indicated by ongoing losses and significant research and development expenses. The financial statements detail the company's financial position, operational performance, and cash flows, reflecting its investment in pipeline development and early-stage commercialization efforts. While no specific revenue figures or profit/loss details are provided in this overview of the filing's structure, the focus of the MD&A section will be on the company's financial condition, results of operations, and market risk. The risk factors section is particularly important for understanding the inherent uncertainties and potential challenges associated with a biopharmaceutical company at this stage of its lifecycle.

Financial Highlights

39 data points
Beta

Net Income

-$13.24M

EPS (Diluted)

$-0.31

Total Assets

$310.22M

Cash & Equivalents

$74.34M

Free Cash Flow

-$29.29M

Financial Statements
Beta
R&D Expenses$24.27M
Operating Expenses$33.23M
Operating Income-$12.44M
Net Income-$13.24M
EPS (Basic)$-0.31
Shares Outstanding (Basic)42.65M

Key Highlights

  • 1The report contains unaudited condensed consolidated financial statements for the nine months ended September 30, 2011, including Balance Sheets, Statements of Operations and Comprehensive Loss, and Cash Flows.
  • 2Management's Discussion and Analysis (MD&A) is a key section for understanding the company's financial condition, operational results, and liquidity.
  • 3Disclosure regarding market risk provides insights into the company's exposure to changes in market factors like interest rates and foreign currency exchange rates.
  • 4The 'Risk Factors' section (Item 1A) is critical for investors to assess potential challenges, uncertainties, and risks associated with Alnylam's business, including product development, regulatory approvals, and market competition.
  • 5The filing includes information on legal proceedings, which could have a material impact on the company's financial standing.
  • 6The report structure indicates a focus on the company's ongoing operational activities and financial health rather than immediate profitability, typical for a development-stage biopharmaceutical firm.

Frequently Asked Questions

This filing provides a snapshot of Alnylam Pharmaceuticals' financial condition and operational results for the first nine months of 2011. As a development-stage biopharmaceutical company, it is expected to be incurring significant research and development expenses, likely leading to net losses. Investors should review the Condensed Consolidated Statements of Operations and Cash Flows for specific details on revenue, expenses, and cash burn, and the MD&A for management's commentary on the company's financial position and outlook.

The 'Risk Factors' section (Item 1A) is the primary source for understanding the risks. These typically include risks related to the success of drug development, the lengthy and uncertain regulatory approval process, the ability to successfully commercialize products, competition from other pharmaceutical companies, intellectual property challenges, reliance on third-party manufacturers, and the need for future financing.

While the 10-Q provides financial statements and operational discussions, detailed information on the product pipeline and future prospects is usually found within the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' (MD&A) section. This section often elaborates on the progress of ongoing clinical trials, strategic partnerships, and the company's plans for advancing its drug candidates.